Shaperon Receives Approval of HY209 Phase 1 Study for Dementia
Shaperon Receives Approval of HY209 Phase 1 Study for Dementia
  • Hyun Duk Yang
  • 승인 2021.12.02 09:03
  • 댓글 0
이 기사를 공유합니다

HY209, a novel inflammasome inhibitor
Preparing for IPO
샤페론

On November 29, the Korea Ministry of Food and Drug Safety approved the phase 1 clinical trial of HY209 for the treatment of dementia.

HY209 is a novel inflammasome inhibitor developed by Shaperon, a biotech company based in Seoul. The main ingredient of HY209 is taurodeoxycholic acid (a component of bile acids) that can suppress the production of proinflammatory cytokines.

In the pre-clinical studies with the Alzheimer’s disease (AD) mouse models, HY209 reduced the AD pathologies and cognitive dysfunction.

The phase 1 study will start next year and is expected to take about one and a half years to confirm the safety, tolerability, and pharmacokinetics of HY209. A total of 86 healthy volunteers will participate in this clinical trial.

Meanwhile, Shaperon passed the technology evaluation for KOSDAQ listing in November and has a plan to proceed with the Initial Public Offering (IPO) in the first half of next year.



댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.